Have we found the ultimate risk factor for breast cancer?

Journal of Clinical Oncology

Volumn 24, Issue 12, 2006, Pages 1791-1794

  Vogel, Victor G ^a   Taioli, Emanuela ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN; ANDROSTENEDIONE; AROMATASE INHIBITOR; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; HORMONE BINDING PROTEIN; LETROZOLE; PRASTERONE; PRASTERONE SULFATE; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TESTOSTERONE; TESTOSTERONE 17BETA DEHYDROGENASE;

BODY MASS; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; DNA POLYMORPHISM; EDITORIAL; GENOTYPE; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ADULT; AGED; BREAST TUMOR; DRINKING BEHAVIOR; FEMALE; GENETIC PREDISPOSITION; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NOTE; PARITY; PHYSIOLOGY; PREGNANCY;

ADULT; AGED; ALCOHOL DRINKING; BREAST NEOPLASMS; ESTRADIOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PARITY; PREGNANCY; RISK FACTORS;

EID: 33646348204     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.4122     Document Type: Editorial

References (26)

1. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 21:427-433, 2000
2. The Endogenous Hormones and Breast Cancer Collaborative: Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 94:606-616, 2002
3. Hankinson SE, Willett WC, Manson JE, et al: Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90:1292-1299, 1998
4. Eliassen AH, Missmer SA, Tworoger SS, et al: Endogenous steroid hormone concentrations and risk of breast cancer: Does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 24:1823-1830, 2006
5. Missmer SA, Eliassen AH, Barbieri RL, et al: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856-1865, 2004
6. Cauley JA, Lucas FL, Kuller LH, et al: Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Ann Intern Med 130:270-277, 1999
7. Lippman ME, Krueger KA, Eckert S, et al: Indicators of lifetime estrogen exposure: Effect on breast cancer incidence and interaction with raloxifene therapy in the Multiple Outcomes of Raloxifene Evaluation study participants. J Clin Oncol 19:3111-3116, 2001
8. Cummings SR, Duong T, Kenyon E, et al: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220, 2002
9. Cummings SR, Lee JS, Lui L-Y, et al: Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: A long-term prospective study. Cancer Epidemiol Biomarkers Prev 14:1047-1051, 2005
10. Tworoger SS, Missmer SA, Barbieri RL, et al: Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 97:595-602, 2005
11. The Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
12. The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712, 2004
13. Beattie MS, Costantino JP, Vogel V, et al: Endogenous sex hormones and response to tamoxifen: An ancillary study in the breast cancer prevention trial (P-01). J Natl Cancer Inst 98:110-115, 2006
14. Wang W, John EM, Ingles SA: Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev 14:2990-2994, 2005
15. Le Marchand L, Donlon T, Kolonel LN, et al: Estrogen metabolism-related genes and breast cancer risk: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 14:1998-2003, 2005
16. Lurie G, Maskarinec G, Kaaks R, et al: Polymorphisms associated with serum estrogens measured multiple times during a two-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 14:1521-1527, 2005
17. Setiawan VW, Hankinson SE, Colditz GA, et al: HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 13:213-219, 2004
18. Tworoger SS, Chubak J, Aiello EJ, et al: Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13:94-101, 2004
19. Kabat GC, O'Leary ES, Gammon MD, et al: Estrogen metabolism and breast cancer. Epidemiology 17:80-88, 2006
20. Kaaks R, Rinaldi S, Key TJ, et al: Postmenopausal serum androgens, oestrogens and breast cancer risk: The European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12:1071-1082, 2005
21. Page JH, Colditz GA, Rifai N, et al: Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev 13:1032-1036, 2004
22. Tworoger SS, Eliassen AH, Rosner B, et al: Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64:6814-6819, 2004
23. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
24. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
25. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
26. Freedman AN, Graubard BI, Rao SR, et al: Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95:526-532, 2003